Intervention

Psilocybin 25 mg

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting0

Common conditions5

Lead sponsors shown3

Clinical trials

3 shown

Psilocybin Therapy for Methamphetamine Use Disorder and HIVNCT07756736 · 2026-11-01

NOT_YET_RECRUITING

Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use DisorderNCT07405606 · 2026-03-01

NOT_YET_RECRUITING

Psilocybin for Major Depressive Disorder (MDD)NCT06308653 · 2024-03-13

ACTIVE_NOT_RECRUITING

Common conditions

Alcohol Use Disorder (AUD)1 Depressive Disorder, Major1 Human Immunodeficiency Virus (HIV)1 Major Depressive Disorder (MDD)1 Methamphetamine Use Disorder1

Leading sponsors

Centre for Addiction and Mental Health1 Nicky Mehtani, MD, MPH1 Usona Institute1

Trial status mix

NOT_YET_RECRUITING2

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE22

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.